Macquarie Lowers Hologic to Neutral (HOLX)

By admin | 6 years ago

Hologic (NASDAQ: HOLX) was downgraded by investment analysts at Macquarie from an “outperform” rating to a “neutral” rating in a note issued to investors on Tuesday.

Hologic traded down 2.29% on Tuesday, hitting $18.37. Hologic has a 1-year low of $13.90 and a 1-year high of $23.24. The company has a market cap of $4.846 billion and a price-to-earnings ratio of 29.89.

The company last announced its quarterly results on Monday, April 30th. It reported $0.33 earnings per share (EPS) for the previous quarter, meeting the Thomson Reuters consensus estimate of $0.33 EPS. The company’s quarterly revenue was up 7.4% on a year-over-year basis. Analysts expect that Hologic will post $0.36 EPS next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at William Blair initiated coverage on shares of Hologic in a research note to investors on Thursday, April 5th. They set an “outperform” rating on the stock. Separately, analysts at Bank of America (NYSE: BAC) initiated coverage on shares of Hologic in a research note to investors on Wednesday, April 4th. They set a “buy” rating and a $26.00 price target on the stock. Finally, analysts at Dougherty & Co upgraded shares of Hologic from a “neutral” rating to a “buy” rating in a research note to investors on Thursday, March 1st.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics, medical imaging systems and surgical products for the healthcare needs of women.

About the author